Sorrento Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Sorrento Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 8 completed early-phase tilt top decile by trial count

Sorrento Therapeutics: 10 sponsored US clinical trials, none currently recruiting.

Sorrento Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Intractable Cancer Pain, with 1 trials.

Top-decile sponsor footprint

Sorrento Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

NCT05308225
COMPLETED Phase 2

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

NCT04906694
COMPLETED Phase 1

Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19

NCT04486001
COMPLETED Phase 2

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

NCT04440007
TERMINATED Phase 1

Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

NCT03818165
COMPLETED Phase 1

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916
COMPLETED Phase 1

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

NCT03542838
COMPLETED Phase 1

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)

NCT03229798
COMPLETED Phase 1

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

NCT03226574
COMPLETED NA

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

NCT02064829

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 2

Therapeutic Areas

Intractable Cancer Pain 1
Relapsed or Refractory Multiple Myeloma 1
Multiple Myeloma 1
Migraine Disorders 1

How the Sorrento Therapeutics early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Intractable Cancer Pain (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Sorrento Therapeutics: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Sorrento Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Sorrento TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Sorrento Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sorrento Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sorrento Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Sorrento Therapeutics or any single study.

  • None of Sorrento Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Intractable Cancer Pain is the condition Sorrento Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Intractable Cancer Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sorrento Therapeutics pipeline card: 10 registered trials from official public datasets.Report a data error.